ACE Inhibitors News and Research

RSS
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Radical shift required in use of heart medicine worldwide

Radical shift required in use of heart medicine worldwide

Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

Commonly prescribed drug also lowers blood pressure when combined with diuretic

Commonly prescribed drug also lowers blood pressure when combined with diuretic

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

FDA approves new heart failure drug

FDA approves new heart failure drug

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Statins reduce risk of death by 67% in CABG surgery

Statins reduce risk of death by 67% in CABG surgery

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Novartis’ heart failure medicine LCZ696 granted FDA priority review

Novartis’ heart failure medicine LCZ696 granted FDA priority review

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Study suggests that beta blockers may benefit patients suffering from HFPEF

Study suggests that beta blockers may benefit patients suffering from HFPEF

Women prescribed different medication than men to bring down blood pressure

Women prescribed different medication than men to bring down blood pressure